AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00849563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Risk Assessment
Description: patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
Study NCT00567203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3463275
Description: PF-3463275 25mg
Study NCT00567203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02304705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg three times daily by mouth for 90 days
Study NCT02304705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule three times daily by mouth for 90 days
Study NCT04136821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oceanix
Description: Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
Study NCT04136821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
Study NCT04136821 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: 6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
Study NCT03891771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring sensors
Description: This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
Study NCT00736268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based Enhanced Coping Skills Training (CST)
Description: Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
Study NCT00736268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Medical Care and COPD education and symptom monitoring (UMC)
Description: COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
Study NCT04410601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
Study NCT04410601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy
Description: DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
Study NCT03275597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
Study NCT03275597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.
Study NCT03275597 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
Study NCT03714698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercise group
Description: Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
Study NCT03714698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
Study NCT01367288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa + Neoadjuvant therapy
Description: 4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
Study NCT01367288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
Study NCT01367288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
Study NCT01015040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate suspension
Description: Oral
Study NCT01015040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate tablet
Description: Oral
Study NCT04415320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396(Ensartinib)
Description: All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
Study NCT00559312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol combination
Description: Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
Study NCT00559312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Diskus inhaler, twice daily, 6-week duration
Study NCT00954187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
Study NCT00954187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 50 mg PO TID
Study NCT01242579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc/Dapivirine Gel
Description: Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
Study NCT01242579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Gel
Description: Dapivirine vaginal gel containing 2.5g
Study NCT01242579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc Vaginal Gel
Description: Maraviroc vaginal gel containing 2.5g
Study NCT01242579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Gel
Description: Matching placebo gel containing 2.5g
Study NCT02914340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Study NCT00316602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: Subjects receiving two subcutaneous vaccinations
Study NCT01663922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir as Victrelis(r) 200mg capsules
Study NCT01663922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St John's Wort
Description: Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
Study NCT00834626 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ileal Interposition with Sleeve Gastrectomy
Description: Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
Study NCT01069653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402-restricted CDCA1 and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
Study NCT03940703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
Study NCT03940703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Participants received Osimertinib at a dose of 80 mg orally once daily.
Study NCT01385852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microcoaxial phacoemulsification
Description: conventional longitudinal ultrasound
Study NCT04795765 — intervention group
Intervention type: PROCEDURE
Intervention: SpineJack system
Description: For use in the reduction of painful osteoporotic vertebral compression fractures.
Study NCT04795765 — intervention group
Intervention type: PROCEDURE
Intervention: Balloon kyphoplasty
Description: Treatment of osteoporotic vertebral compression fractures.
Study NCT04795765 — intervention group
Intervention type: PROCEDURE
Intervention: Vertebroplasty
Description: Treatment of osteoporotic vertebral compression fractures.
Study NCT03309540 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Study NCT03309540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Study NCT03806881 — intervention group
Intervention type: DEVICE
Intervention: reversed glenoid prothesis
Description: All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
Study NCT00858377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1- Dose Escalation
Description: AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Study NCT00858377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1- Dose Expansion
Description: AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Study NCT03917056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy using long needle
Description: Participants were treated with CAES using long needle.
Study NCT03917056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy using short needle
Description: Participants were treated with CAES using short needle.
Study NCT04611009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor training
Description: In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
Study NCT04611009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness exercises
Description: The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
Study NCT02590900 — intervention group
Intervention type: DRUG
Intervention: intravenous paracetamol (acetaminophen)
Description: paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
Study NCT02013921 — intervention group
Intervention type: OTHER
Intervention: Physical activity
Study NCT03936569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed Toothpaste
Description: Marketed stannous fluoride (0.454%) toothpaste
Study NCT03936569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marketed Cavity Protection Toothpaste
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Study NCT02037672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study NCT02037672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and roflumilast
Study NCT03698292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: Prokinetic Drug
Study NCT03698292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Prokinetic Drug
Study NCT03021746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Support (DSMS)
Study NCT02491138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appearance-based intervention
Study NCT02491138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pamphlets
Study NCT03427710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CiVi007
Description: cholesterol lowering drug
Study NCT03427710 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to CiVi007
Study NCT01768325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-TCB needle (QuickCore) standard of care
Description: * The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications
Study NCT01768325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Guided biopsy needle (ProCore)
Description: * The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications
Study NCT01288313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
Study NCT01288313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
Study NCT01288313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
Study NCT01288313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional intervention
Description: Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
Study NCT00170209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
Study NCT00170209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
Study NCT00325741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: 1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
Study NCT00264147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
Study NCT01208389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: voretigene neparvovec-rzyl
Description: One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
Study NCT04020185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
Study NCT04020185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor (ICI)
Description: Administered according to product label
Study NCT04020185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immuno-oncology (IO) therapy
Description: Administered according to product label